Apimeds Pharmaceuticals US, Inc
Apimeds Pharmaceuticals US, Inc (APUS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · APUS · as of Sep 30, 2025
Ownership Breakdown
8
Institutional Holders
▲ 2 vs Q2
$711,810
Total Inst. Value
▲ $221,594 vs Q2
1.26M
Shares Outstanding
freeFloat 18.01%
399,983
13F Shares Held
▲ 121,452 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
APUS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
HEMENWAY TRUST CO LLC pharmaceutical preparations | 250.0K | 22.97% | 22.97% | $445.00M | Nov 7, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 59.0K | 5.42% | 5.42% | $105.00M | Nov 7, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 30.8K | 2.83% | 2.83% | $54.74M | Nov 12, 2025 | NEW |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 27.9K | 2.56% | 2.56% | $49.65M | Nov 13, 2025 | NEW |
XTX TOPCO LTD pharmaceutical preparations | 18.7K | 1.72% | 1.72% | $33.35M | Nov 14, 2025 | NEW |
HRT FINANCIAL LP pharmaceutical preparations | 13.6K | 1.25% | 1.25% | $24.00M | Nov 14, 2025 | NEW |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 29 | 0.00% | 0.00% | $52,000 | Feb 3, 2026 | — held |
JPMORGAN CHASE & CO pharmaceutical preparations | 8 | 0.00% | 0.00% | $14,000 | Nov 26, 2025 | ▲ 3 |
YORKVILLE ADVISORS GLOBAL, LP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 18, 2025 | EXIT |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
1
Increased
+3 shares6
New Positions
first time holders0
Decreased
−0 shares4
Sold Out
fully exitedNet shares change (top 50)
+3
+3 / −0
Net new holders
+3
6 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
APUS insider trading · insider activity
Source: SEC Form 4
12
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Weintraub Bennett director | Nov 11, 2025 | Award | 10,000 | $2.67 | $26.7K | 10.0K | Form 4 ↗ |
Yoon Hankil director | Nov 11, 2025 | Award | 10,000 | $2.67 | $26.7K | 10.0K | Form 4 ↗ |
Koo Jakap director | Nov 11, 2025 | Award | 10,000 | $2.67 | $26.7K | 10.0K | Form 4 ↗ |
O'DONNELL CAROL A director | Nov 11, 2025 | Award | 10,000 | $2.67 | $26.7K | 10.0K | Form 4 ↗ |
Kogan Elona director | Nov 11, 2025 | Award | 10,000 | $2.67 | $26.7K | 10.0K | Form 4 ↗ |
Kogan Elona director | Oct 15, 2025 | Award | 3,000 | $1.92 | $5.8K | 3.0K | Form 4 ↗ |
O'DONNELL CAROL A director | Oct 15, 2025 | Award | 3,000 | $1.92 | $5.8K | 3.0K | Form 4 ↗ |
Koo Jakap director | Oct 15, 2025 | Award | 3,000 | $1.92 | $5.8K | 3.0K | Form 4 ↗ |
Weintraub Bennett director | Oct 15, 2025 | Award | 3,000 | $1.92 | $5.8K | 3.0K | Form 4 ↗ |
Kim Christopher Chairman and CMO | Oct 15, 2025 | Award | 3,000 | $1.92 | $5.8K | 3.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Apimeds Pharmaceuticals US, Inc (APUS) is primarily owned by institutional investors, who hold approximately 31.8% of total shares outstanding. Company insiders own approximately 81.99%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Apimeds Pharmaceuticals US, Inc is HEMENWAY TRUST CO LLC, holding approximately 250,000 shares — equal to 22.97% of outstanding shares — as of September 30, 2025.
A total of 8 institutional investors currently hold APUS stock, with a combined institutional value of approximately $711,810 as of the most recent 13F filing period.
Frequently asked questions
APUS ownershipApimeds Pharmaceuticals US, Inc (APUS) is primarily owned by institutional investors, who hold approximately 31.8% of shares. The largest shareholder is HEMENWAY TRUST CO LLC with a 22.97% stake. Company insiders hold 81.99%. Data sourced from SEC Form 13F as of September 30, 2025.